Factors Predicting Erythropoietin Responsiveness in Children on Hemodialysis at Sohag University Hospital

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05312346
Collaborator
(none)
50
1
12
4.2

Study Details

Study Description

Brief Summary

Anemia is common in patients on hemodialysis (HD) due to lack of erythropoietin (EPO) synthesis and iron deficiency is occurring in HD patients due to chronic blood loss through the dialysis circuit, repeated blood sampling, shortened red blood cell life span and lack of adherence to treatment .

Anemia is one of the most important complications that affects morbidity and mortality in chronic kidney disease (CKD) patients. It has significant impacts on those patients such as fatigue, weakness, shortness of breath, decreased quality of life, exercise capacity and physical activity, growth retardation and decreased cognitive functions, left ventricular hypertrophy, and congestive heart failure So, proper management of anemia is very important .

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: seum zinic,vit B12, parathyriod function

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
University Hospital
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2023

Arms and Interventions

Arm Intervention/Treatment
responsiveness to erythropoietin stimulating agent

we evolute responsiveness of patients on hemodialysis for erythropoietin stimulating agents or not and factors effecting this response

Diagnostic Test: seum zinic,vit B12, parathyriod function
seum zinic,vit B12, parathyriod function

Outcome Measures

Primary Outcome Measures

  1. Hb g/dl [one year]

    measure hemoglobin level

  2. Iron profile [one year]

    measure iron profile on blood

  3. Serum creatinine [one year]

    serum creatinine

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Year and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • (1) patients started dialysis in the age range of 1-18years. (2) Patient will be on regular hemodialysis.
Exclusion Criteria:
  • Children who have no other co existent hematological disorder .

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sohag University Hospital Sohag Egypt

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hanan Nagdy Fawzy, pediatric specialist, Sohag University
ClinicalTrials.gov Identifier:
NCT05312346
Other Study ID Numbers:
  • Soh-Med-22-03-04
First Posted:
Apr 5, 2022
Last Update Posted:
Apr 5, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 5, 2022